²¹¹At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges

Hugo Levillain, Anne Royer Moës, Cristiana Gameiro-Paris, Antero Abrunhosa, Tom Deakin, Geraldine Gebhart, Matthias M. Herth, Jean-François Gestin, Ferid Haddad, Andreas Ingemann Jensen, Rebecca Lo Bue, Renata Mikolajczak, Adrian Otamendi, Katie Staunton-Mann, Kevin Tabury & Patrick Flamen on behalf of the Accelerate.EU consortium

Targeted Alpha Therapy (TAT) holds considerable promise for precision oncology, yet its clinical deployment in Europe remains limited. Beyond scientific considerations, progress is constrained by fragmentation across the radiopharmaceutical value chain, encompassing radionuclide production, radiochemistry, preclinical validation, clinical development, regulatory frameworks, infrastructure, and workforce training.